Angiogenic growth factors, vascular endothelial growth factor (VEGF) and angiopoietin-1 (Ang1) could decrease myocardial infarct size, which was assumed to be related with newly formed capillaries. We doubted that these capillaries could do this solely and the potential protective mechanisms of VEGF and Ang1 on myocardium need to be evaluated. Three types of adenoviruses encoding human VEGF 165 (Ad-VEGF 165 ), human angiopoietin-1 (Ad-Ang1) and green fluorescent protein (Ad-GFP, as a parallel control) were constructed. Experiments were taken both in vitro and in vivo. As in vitro, the antiapoptosis effect of VEGF 165 , Ang1 and VEGF 165 +Ang1 on cardiac myoblasts was observed, which seemed to be related with the activation of phosphatidylinositol-3 kinase and Bcl-2 pathways. As in vivo, adenoviruses were intramyocardially injected immediately after the ligation of the left anterior descending coronay arteries in rats. The results showed positive effect of VEGF 165 , Ang1 and VEGF 165 +Ang1 on decreasing the myocardial infarct size at the 7th day. Myocardial PI-3K activity and Bcl-2 expression were elevated relatively at the 3rd day. The protective effect of VEGF 165 and Ang1 on the myocardium may broaden their functional research and contribute to their clinical use in the future.
Introduction
A few studies indicated that angiogenic growth factors, vascular endothelial growth factor (VEGF) and angiopoietin-1 (Ang1) could reduce myocardial infarct size, and this effect was assumed to be related with their therapeutic angiogenesis. 1, 2 Nevertheless, newly formed vessels in the above studies were mainly capillaries whose efficacy in improving blood perfusion was inconclusive. For instance, Hershey et al 3 reported that newly formed vessels induced by VEGF were insufficient for the improving of collateral blood flow. Thus, the mechanism that VEGF and Ang1 decrease myocardial infarct size cannot be completely concluded as angiogenesis. There should be some other important mechanisms among which potential protective effects of VEGF and Ang1 on myocardium were possible. Furthermore, VEGF receptors (Flk-1, flt-1) and Ang1 receptor (Tie-2) were found to be exclusively distributed in endothelial cells. 4, 5 This made the mechanisms more complicated. To address these issues, the experiment was carried out firstly in vitro. We found that VEGF 165 and Ang1 protected cardiac myoblasts from apoptosis, which was related with the activation of phosphatidylinositol-3 kinase (PI-3K) and the upregulation of Bcl-2 expression, and these effects were receptor-independent in the case of Ang1. After that, we noticed that Matsui et al 6 had proved that the activation of Akt (downstream target of PI-3K) could reduce myocardial infarct size in an in vivo Akt gene transfer model. We postulated that the mechanisms of VEGF 165 and Ang1 to reduce myocardial infarct size might be related with the activation of PI-3K in myocardium. In the subsequent in vivo experiment, two recombinant adenoviruses encoding human VEGF 165 (Ad-VEGF 165 ) and Ang1 (Ad-Ang1) were injected into rat hearts subjected to permanent coronary ligation. Results showed that gene transfer of VEGF 165 , Ang1 or both could decrease myocardial infarct size, and this was related with the activation of PI-3K and Bcl-2 pathways in the myocardium.
Results

VEGF 165 and Ang1 expression in transfected H9C2 cells
To confirm the efficiency of Ad-VEGF 165 and Ad-Ang1, we analyzed the gene expression of transfected H9C2 cells by detecting target proteins using Western blot assay. VEGF 165 and Ang1 proteins were detected 24 h after gene transfection as a secreted pattern (Figure 1a) . Blank represented normally cultured cells without gene transfection. (Figure 2 ).
VEGF 165 and Ang1 decreased myocardial infarct size
In total, 48 rats were studied for the determination of myocardial infarct size with 27% surgical mortality rate after coronary ligation and intramyocardial injection in each group. Analysis of myocardial infarct size was performed in 35 hearts (seven for each groups). The ratio (heart weight integrated) of risk area (RA) to total left ventricle area (LA) was of no significant difference among L, L+GFP, L+VEGF 165 , L+Ang1 and L+VEG-F 165 +Ang1 groups (40.674.9, 43.0712.7, 44.1710.6, 51.4712.9 and 40.578.5, P40.05, Figure 3 ). The ratio (heart weight integrated) of infarct area (IA) to risk area (RA) was of no difference between L and L+GFP groups (48.5715.8 versus 48.6716.0, P ¼ 0.99), but was significantly smaller in L+VEGF 165 , L+Ang1 and L+VEGF 165 +Ang1 groups than that in the L+GFP group (30.0714.4, VEGF 165 and angiopoietin-1 L Zhou et al 14.5711.6 and 9.576.5 versus 48.6716.0, Po0.01, Figure 3 ). Furthermore, IA/RA (%) was even smaller in L+Ang1 and L+VEGF 165 +Ang1 groups as compared with the L+VEGF 165 group (14.5711.6 and 9.576.5 versus 30.0714.4, Po0.01, Figure 3 ). There was no significant difference of IA/RA (%) between L+Ang1 and L+VEGF 165 +Ang1 groups (14.5711.6 versus 9.576.5, P ¼ 0.45, Figure 3 ).
PI-3K activity after VEGF 165 Figure 5 ) and further activated in the L+VEGF 165 +Ang1 group as compared with the L+VEGF 165 group (24.978.7 versus 16.476.8, Po0.05, Figure 5 ). However, elevated PI-3K activity in L+Ang1 and L+VEGF 165 +Ang1 groups were of no significant difference (24.4711.8 versus 24.978.7, P ¼ 0.92, Figure 5 ).
Bcl-2 expression after VEGF 165 and Ang1 gene transfection
Bcl-2 expression in H9C2 cells was upregulated 24 h after gene transfection in VEGF 165 Figure 6 ). Blank represented normally cultured cells without gene transfection. Bcl-2 expression in myocardium was significantly upregulated in the L+Ang1 and L+VEGF 165 +Ang1 groups as compared with the L+GFP group (6.971.9 and 6.372.4 versus 2.672.2, Po0.01, Figure 7 ). Furthermore, Bcl-2 expression level was even higher in L+Ang1 and L+VEGF 165 +Ang1 Figure 8 ).
Discussion
VEGF and Ang1 were reported to be able to decrease myocardial infarct size, and this was assumed to be related with their angiogenic properties. 1,2 However, newly formed vessels were mainly capillaries that were thought to be unable to fulfill this protective effect solely. Potential protective effects of VEGF and Ang1 on myocardium are probable. In order to testify this hypothesis, experiments were taken both in vitro and in vivo. As in in vitro study, H9C2 cell line was applied as a substitute for rat cardiomyocyte. Although originated from embryonic rat heart tissue and not completely the same as the primary cultured cardiomyocytes, H9C2 cells are acceptable and widely used in the research of myocardium. However, difference does exist between Figure 1b) , and Ray et al 5 found that rat myocardium express neither Flk-1 nor Tie-2. Nevertheless, as a widely accepted substitute for rat cardiomyocyte in in vitro study, H9C2 cell line provided us with some important information that guided us in in vivo study. Data revealed that, although Tie-2 did not express in H9C2 cells, Ang1 could activate intracellular PI-3K and Bcl-2 pathways and protected H9C2 cells from apoptosis. This implicated that the protective effect of Ang1 on H9C2 cells was receptor independent. Furthermore, in vivo findings showed that, although rat myocardium did not express Flk-1 and Tie-2, VEGF 165 could activate the myocardial PI-3K pathway and Ang1 could both activate the myocardial PI-3K and Bcl-2 pathways, and decrease myocardial infarct size. This could also be served as an implication that the protective effects of VEGF 165 and Ang1 on myocardium were receptor independent. This consistency of in vitro and in vivo results suggested that the H9C2 cell line was a qualified substitute for rat cardiomyocyte in our study. Additionally, results showed that VEGF 165 could upregulate Bcl-2 in H9C2 cells ( Figure 6 ) but not in rat myocardium ( Figure 7 ). This may be due to the different distribution pattern of Flk-1 in H9C2 cells and myocardium (H9C2 cells express Flk-1 while myocardium does not). So, in vitro upregulation of Bcl-2 by VEGF 165 seemed to be receptor dependent. As in vivo, VEGF 165 could only activate PI-3K by receptor-independent mechanisms, while Ang1 activated both PI-3K and Bcl-2 pathways by receptor-independent mechanisms. This may also be the reason that Ang1 exhibited greater protective effect against infarction as compared with VEGF 165 .
As to the PI-3K and Bcl-2 signaling pathways, their crucial roles in antiapoptosis and cell-surviving processes have been well documented.
7-9 PI-3K is a heterodimer of two subunits, catalytic and regulatory, with molecular weights of 110 kDa (p110) and 85 kDa (p85), respectively. The antiapoptosis effect of PI-3K is realized by the activation of its downstream target Akt. 10 As myocardium did not express Flk-1, flt-1 and Tie-2, 4, 5 we wondered how VEGF 165 and Ang1 activated PI-3K in the myocardium. About this point, Carlson and Hutchings groups' studies might provide us with some meaningful elicitations. In their studies, Ang1 and VEGF were found to mediate endothelial cell adhesion and survival through interactions with integrins. 11, 12 Since various kinds of integrins had been proved to express in adult myocardium, 13 interaction of integrins with VEGF 165 or Ang1 might be the first step that VEGF 165 or Ang1 activated the intracellular PI-3K pathway. Integrins can be served as adhesion receptors that transduce biochemical signals into the cell. These signaling events regulate cellular processes such as proliferation, apoptosis, migration and spreading. Focal adhesion kinase (FAK) is an important protein tyrosine kinase that mediates several integrin signaling pathways.
14,15 PI-3K activation resulting from its binding to the FAK Tyr-397 site has been implicated as a downstream FAK signaling event that confers a resistance to apoptosis. 16 Therefore, a VEGF 165 or Ang1/integrins/FAK pathway might lead to the activation of PI-3K. However, precise signaling pathways need to be further investigated.
Although VEGF 165 and Ang1 were found to both activate PI-3K and upregulate Bcl-2 in H9C2 cells, the relationship between PI-3K and Bcl-2 was unclear. A previous study of Pugazhenthi group's indicated that Akt could enhance CREB activity and consequently upregulate Bcl-2 expression through binding with CRE contained in the promoter region of Bcl-2 (that is PI-3K/ Akt/CREB/Bcl-2 pathway). 17 But, Catz et al 18 declared that NF-kB could transcriptionally regulate Bcl-2 gene through binding with a NF-kB site in the promoter region of Bcl-2 (that is NF-kB/Bcl-2 pathway; PI-3K and Bcl-2 are independent of each other). To make things clear, we took another study in H9C2 cells. Results (unpublished) showed that upregulation of Bcl-2 induced by VEGF 165 and Ang1 was not altered by a pretreatment of wortmannin (specific inhibitor of PI-3K). This meant that PI-3K activation and Bcl-2 upregulation stimulated by VEGF 165 and Ang1 were two independent signaling pathways in H9C2 cells. As it was impracticable for the inhibition of myocardial PI-3K in vivo by the use of wortmannin, evaluation of NF-kB-binding activity and Bcl-2 expression was used to indirectly reflect the relationship between PI-3K and Bcl-2 in vivo. At 3 days after Ad-VEGF 165 +Ad-Ang1 transfection, a significant increase of NF-kB/DNA-binding activity (Figure 8 ) accompanied by an upregulated Bcl-2 expression (Figure 7 ) was observed in the myocardium. Since Matsui et al 6 had found that myocardial Bcl-2 expression was not altered by the expression of Akt after in vivo Akt gene transfection, the above finding implicated that myocardial Bcl-2 expression was regulated by NF-kB (that is NF-kB/Bcl-2 pathway). All these suggested that PI-3K activation and Bcl-2 upregulation stimulated by Ang1 in myocardium were also two independent signaling pathways. Additionally, we noticed that there was an inconsistency between upregulated Bcl-2 expression (Figure 7 ) and elevated NFkB/DNA-binding activity (Figure 8 ) in the L+Ang1 group, which was thought to be caused by the late check time of NF-kB, since nuclear translocation of NF-kB is transient and prompt following stimulation.
Including the above-mentioned mechanism, other possible mechanisms might be also involved in the decreasing of myocardial infarct size. In the present study, Ad-VEGF 165 and Ad-Ang1 were injected into myocardium immediately after the LAD ligation. It might take several hours for gene transfection, protein expression and biological outcomes. As expressed VEGF 165 and Ang1 could only protect myocardium at risk from death, how could they decrease infarct size formed in the early stage of ischemic injury? Study of Asahara group's indicated that, following VEGF administration in vivo, an increase in circulating bone marrow-derived endothelial progenitor cells (EPCs) was observed. 19 Also, Orlic et al 20 proved that transplanted bone marrow cells (Lin À /c-kit + ) could differentiate into cardiac myocytes in heart. Thus, VEGF 165 -and Ang1-mobilized bone marrow cells might migrate into the heart, differentiate into cardiomyocytes and decrease myocardial infarct size. Additionally, Voermans et al 21 indicated that efficient migration of hematopoietic progenitor CD34 + cells across the bone marrow endothelium is mediated by b 1 -integrins and b 2 -integrins. Thus, the above-supposed process might be mediated by integrins. Another possibility lies in the proliferation of cardiomyocytes. Although Beltrami et al 22 found that a low level of cardiomyocyte proliferation existed in adult heart after myocardial infarction, VEGF 165 and Ang1 might accelerate this process. In summary, VEGF 165 and Ang1 could decrease myocardial infarct size, which was related with the activation of myocardial PI-3K and Bcl-2 pathways. This is a new mechanism ever known in VEGF 165 and Ang1 functional research. The protective effects of these two angiogenic growth factors on myocardium would be useful for their clinical application.
Materials and methods
Adenoviral vectors
Two replication-deficient adenoviruses encoding human Ang1 (Ad-Ang1) and VEGF 165 (Ad-VEGF 165 ) were generated by homologous recombination. 23 Gene expression was driven by a cytomegalovirus promoter/ enhancer. Ad-GFP was a parallel control during gene transfection. A Tissue Culture Infectious Dose 50 (TCID 50 ) method was used to determine the titer.
Cell culture and gene transfection
Human umbilical vein endothelial cells (HUVEC, Clonetics, Inc.) were grown in modified MCDB 131 medium supplemented with 12 mg/ml bovine brain extracts (BBE), 0.01 mg/ml human epithelial growth factor (hEGF), 1 mg/ml hydrocortisone, 2% FBS and 50 mg/ml gentamycin (as recommended by the HUVEC culture protocol of Clonetics). H9C2 cells, embryonic rat heartderived myoblasts (American Type Culture Collection), were grown in RPMI-1640 medium (Mediatech, Inc.) supplemented with 10% NCS (HyClone, Inc.) and 1% FBS (HyClone, Inc.). Prior to transfection, H9C2 cells were washed with plain RPMI-1640 medium. Then, Ad-VEGF 165 , Ad-Ang1 and Ad-GFP were added into the cells at a Multiplicity of Infection (MOI, plaque-forming unit (PFU)/cell) of 20:1. As for double transfection with VEGF 165 and Ang1, both Ad-VEGF 165 and Ad-Ang1 were added at an MOI of 20:1. Cells were then incubated at 371C (5% CO 2 ) in RPMI-1640 medium without serum.
Western blot analysis
As for the detection of VEGF 165 and Ang1, H9C2 cells and culture medium were harvested, respectively, 24 h after transfection. Whole-cell lysates and whole culture medium concentrates were analyzed by 12.5% SDS-PAGE. As for the detection of Flk-1 and Tie-2, H9C2 cells and HUVECs were harvested at 80% confluency. Cell lysates were analyzed by 7.5% SDS-PAGE. As for the detection of Bcl-2, H9C2 cells and rat hearts were harvested 24 and 72 h, respectively, after transfection. Heart tissues were dispersed in Tris-buffered saline (TBS) and blood was washed out before lyzing. Myocardial and H9C2 cell lysates were clarified by centrifugation at 15 000 g for 3 min before analyzing by 12.5% SDS-PAGE. Proteins were transferred to nitrocellulose membranes (Amersham Biosciences) before blocking with 5% nonfat dried milk in TBS. Membranes were immunoblotted with polyclonal antibodies of VEGF 165 , Ang1, Flk-1, Tie-2 and Bcl-2 (Santacruz Biotechnology), and visualized by chemiluminescence system (Amersham Biosciences) using horseradish peroxidase-conjugated anti-goat or anti-rabbit IgG (Sigma-Aldrich Corporation). Quantitation was determined by densitometry.
DNA ladder assay
H9C2 cell culture and gene transfection were indicated previously. At 24 h after gene transfection, H 2 O 2 (Fisher, Inc.) was added at a final concentration of 100 mmol/l to induce apoptosis. After 6 h, adherent and detached cells were harvested and then lyzed with 1% sodium lauroyl sarcosine, 250 mmol/l EDTA, 50 mmol/l Tris-HCl, pH 8.0. After the treatment of 0.1 mg/ml RNase A for 1 h at 371C and 0.2 mg/ml proteinase K for 3 h at 561C, genomic DNA was extracted with phenol/chloroform and dissolved in TE buffer (10 mmol/l Tris Cl, 1 mmol/l EDTA, pH 8.0). DNA fragmentation was analyzed in 1.8% agarose gels.
Animal model
Male Sprague-Dawley rats (Shanghai laboratory animal center, Chinese Academy Sciences) weighing 250-350 g were intraperitoneally anesthetized with chloral hydrate (36 mg/100 g). An anterior thoracotomy was performed to open the pericardium. The left anterior descending coronary artery (LAD) was ligated 5 mm away from the origin of aorta with a 6-0 silk suture (WL Gore & Associates, Inc.). Positive end-expiratory pressure was applied to fully inflate the lungs before the muscle layer and skin were closed separately. The animals were allowed to recover. The University Committee on Animal Care of Nanjing Medical University approved the experimental protocol.
Intramyocardial gene transfection
For infarct size analysis, rats were divided into five groups: ligation (L), L+GFP, L+VEGF 165 , L+Ang1 and L+VEGF 165 +Ang1. For the evaluation of PI-3K activity, NF-kB-binding activity and Bcl-2 expression, rats were divided into seven groups: Normal (no operation), Sham (pericardium open only, without ligation), L, L+GFP, L+VEGF 165 , L+Ang1 and L+VEGF 165 +Ang1. Immediately after the ligation of the LAD, adenoviruses were intramuscularly injected at the left anterior free wall adjacent to the ligated area through a 27-gauge needle (BD Biosciences). After the left ventricle was accessed, the needle was advanced along the left ventricular free wall and viruses were injected over a period of 5-10 s. Ad-GFP or Ad-VEGF 165 injected per rat was 6 Â 10 7 PFU in 0.1 ml phosphate-buffered saline (PBS), while AdAng1 injected per rat was 1.5 Â 10 5 PFU in 0.1 ml PBS.
Myocardial infarct size analysis
At 1 week after gene transfection, rats were heparinized, deeply anesthetized and were put to death by rapid excision of the heart. Blood was washed out from the heart by PBS through aorta. Infarct size measuring by the tetrazolium method was indicated by Ytrehus et al.
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IA, RA and LA were calculated from enlarged digital micrographs with UTHSCSA ImageTool according to different colors (Pale white ¼ infarct area, Red ¼ living at risk, Blue ¼ normal, Risk area ¼ pale white+red). The ratios (%, heart weight integrated) of IA to RA and RA to LA were calculated. The person who measured the infarct size was unaware of the treatment group.
Immunoprecipitated PI-3K assay
At 24 h after transfection, H9C2 cells were harvested for PI-3K analysis. Preparation of H9C2 cell and myocardium lysates was indicated previously. PI-3K activity Briefly, PI-3K was immunoprecipitated with polyclonal anti-p85 a antibody and protein A-agarose beads (Santacruz Biotechnology). Immunoprecipitates were then incubated in 15 ml of kinase buffer with 6 mCi [g-32 P]ATP (Amersham Biosciences) and 20 mg phosphatidylinositol (Sigma-Aldrich Corporation) for 30 min at 371C. Reaction was stopped and phosphatidylinositol was extracted by chloroform/methanol. Extracted phosphatidylinositol was applied to silica gel TLC plates (Analtech, Inc.), which had been presprayed with 1% potassium oxalate and allowed to dry prior to sample application. TLC plates were developed using a 60:47:11.3:2 mixture of CHCl 3 , MeOH, H 2 O 2 and NH 4 OH, respectively. Developed TLC plates were exposed to X-ray film. PI-3K activity was determined by measuring phosphatidylinositol phosphorylation. Quantitation was determined by densitometry.
Electrophoretic mobility shift assay
After myocardial lysates were collected, nuclear precipitates were re-dissolved in a nuclear protein buffer for 1 h at 41C. Nuclear extracts were clarified by centrifugation at 15 000 g for 10 min. Electrophoretic mobility shift assay (EMSA) was performed to determine NF-kB/ DNA-binding activity using a gel-shift assay system (Promega Corporation) according to the instruction of the manufacturer. Briefly, a double-stranded oligonucleotide for NF-kB was end-labeled with [g-32 P]ATP (Amersham Biosciences). Myocardial nuclear extracts (50 mg) were incubated for 20 min at room temperature with a gel-shift-binding buffer and 32 P-labeled oligonucleotide. The formed DNA-protein complex was separated on 6% native polyacrylamide gels. The gel was transferred to a Whatman 3MM paper, dried, and exposed to X-ray film at À701C with an intensifying screen. Quantitation was determined by densitometry.
Statistical analysis
All results were expressed as mean7s.d. Statistical significance was evaluated by analysis of variance following one-way ANOVA procedure with SPSS11.0. software. A value of Po0.05 was considered to denote statistical significance.
